TEST:

DRP®-5FU

"Allarity Therapeutics, Inc...announced today that the two companies have entered into a Clinical Collaboration Agreement. Under this agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol™ for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP^® companion diagnostics, including its validated DRP^®-5FU companion diagnostic, to potentially select patients for enrollment and treatment in clinical trials of Deflexifol™ as a monotherapy and in combination with other drugs....Under the terms of the Clinical Collaboration Agreement, Allarity will initially support FivepHusion’s planned Phase 1b/2a trial of DEFLOX plus bevacizumab in 1st line treatment of unresectable mCRC, which will be conducted at trial sites in Australia....Financial terms of the clinical collaboration, option and potential license are not disclosed."